Case study: Treating COVID-19 in a patient with multiple myeloma
(American Society of Hematology) A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report, published in Blood Advances, also suggests that blood cancer patients may have atypical COVID-19 symptoms.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
More News: Actemra | Cancer | Cancer & Oncology | China Health | COVID-19 | Hematology | Infectious Diseases | Myeloma | Study